About Chongqing Lummy Pharmaceutical Company

The company was founded in 1999 and listed on the GEM board of the Shenzhen Stock Exchange on October 30, 2009. The stock code is 300006. It is one of the first 28 GEM companies and the first listed company in Chongqing to land on the GEM. The company's main business is pharmaceutical manufacturing. The company has a rich variety of products and a reasonable structure. The company's main products are chemical drugs, covering specialty categories (mainly including anti-tumor drugs, digestive drugs, parenteral nutritional drugs), anti-infectives, etc. It has won the title of “Excellent Digestive System Product Brand in the Chinese Chemical Pharmaceutical Industry” for 4 consecutive years, the honorary title of “Excellent Product Brand for Original Research and Patented Drugs in the Chinese Chemical Pharmaceutical Industry” for 2 consecutive years, and in January 2019, Lai Meishu won the “2019 China Industry-University-Research Cooperation Innovation Achievement Outstanding Achievement Award” with the approval of the China Industry-University-Research Cooperation Innovation Promotion and Award Office. Honorary titles such as “Top 100 Industrial Enterprises in China's Chemical and Pharmaceutical Industry with Comprehensive Strength”, “Excellent Product Brand for Original Research and Patented Drugs in China's Chemical Pharmaceutical Industry”, “Excellent Digestive System Product Brand in China's Chemical Pharmaceutical Industry”, and “Excellent Blood and Hematopoietic System Product Brand in China's Chemical Pharmaceutical Industry”.